查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595651

乾癬藥物市場：按分子、給藥途徑、劑型和作用機制分類 - 2025-2030 年全球預測

Psoriasis Therapeutics Market by Molecule (Biologics, Small Molecules), Route of Administration (Oral, Parenteral, Topical), Dosage Forms, Mechanism of Action - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年乾癬治療市場價值為216.2億美元，預計到2024年將達到237.1億美元，複合年成長率為9.77%，到2030年將達到415.5億美元。

乾癬藥物市場包括多種旨在緩解牛皮癬症狀的治療方法，乾癬是一種慢性自體免疫皮膚病，其特徵為紅色鱗狀斑塊。治療方案著重於控制發炎和皮膚細胞增殖，包括局部用藥、照光治療和全身給藥的藥物，例如針對特定免疫途徑的生物製藥。開發乾癬藥物的必要性源於該疾病對患者生活品質的影響以及常規治療方法的功效和安全性有限。這些治療劑應用於各種環境，包括醫院、專科診所和居家醫療，以解決醫療保健相關的品質改進和經濟負擔問題。乾癬患病率的增加、意識的提高和生物技術的進步推動了市場的擴張。主要影響因素包括患者對有效治療的需求增加、新藥核准以及生技藥品和小分子技術的進步。一個值得注意的機會是個人化醫療的發展，特別是客製化生技藥品，以促進更有效的患者治療結果。市場參與者也正在探索小分子抑制劑和基因治療等新的治療領域，這些領域具有巨大的成長潛力。

主要市場統計
基準年[2023] 216.2億美元
預測年份 [2024] 237.1億美元
預測年份 [2030] 415.5億美元
複合年成長率（%） 9.77%

相反，高昂的治療成本、嚴格的監管流程以及長期使用某些治療方法的副作用等挑戰正在阻礙成長。由於乾癬的慢性性質，患者用藥依從性可能會使市場狀況更加複雜。創新治療方法將探索具有更高療效和安全性的新型生物製藥、用於遠距患者管理的遠端醫療，以及使用人工智慧對患者進行分層和改進治療方法。雖然市場表現出動態和包容性，但持續投資研究和克服挑戰對於永續成長至關重要。鼓勵公司優先考慮策略夥伴關係關係，擴大研發線產品，並參與全面的數位行銷宣傳活動，以抓住新的市場機會。

市場動態：揭示快速發展的乾癬藥物市場的關鍵市場洞察

供需的動態交互作用正在改變乾癬藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 世界老年人口的增加
    • 斑塊型乾癬和乾癬乾癬的盛行率增加
    • 此類治療的優惠報銷政策
  • 市場限制因素
    • 治療藥物高成本
  • 市場機會
    • 處方量和生物製藥核准的增加
    • 新生技藥品和新管線藥物的開發
  • 市場挑戰
    • 藥物可能帶來的健康風險

波特的五力：駕馭乾癬藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對乾癬藥物市場的影響

外部宏觀環境因素在塑造乾癬治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解乾癬治療藥物市場的競爭狀況

對乾癬治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣乾癬治療市場供應商的績效評估

FPNV 定位矩陣是評估乾癬治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，為乾癬治療藥物市場的成功指明道路

對於旨在加強其在全球市場的影響力的公司來說，對乾癬治療藥物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地的老年人口正在增加
      • 斑塊型乾癬和乾癬性關節炎的發生率增加
      • 此類療法的優惠報銷政策
    • 抑制因素
      • 治療費用上漲
    • 機會
      • 生物製藥的處方和核准數量增加
      • 新生技藥品和新管線藥物的新進展
    • 任務
      • 藥物可能帶來的健康風險
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章以分子分類的乾癬治療藥物市場

  • 生物製藥
  • 小分子

第7章乾癬治療藥物市場：依給藥途徑

  • 口服
  • 胃腸外的
  • 話題

第8章按劑型分類的乾癬治療藥物市場

  • 液體
  • 半固體
  • 固體的

第9章乾癬治療藥物市場（依作用機轉）

  • IL阻斷劑
  • PDE4抑制劑
  • 腫瘤壞死因子抑制劑

第10章北美和南美乾癬藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區乾癬藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的乾癬藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Amgen, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Johnson & Johnson services, inc
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc
  • Sun Pharmaceutical Industries Limited
Product Code: MRR-035AB9C0DA46

The Psoriasis Therapeutics Market was valued at USD 21.62 billion in 2023, expected to reach USD 23.71 billion in 2024, and is projected to grow at a CAGR of 9.77%, to USD 41.55 billion by 2030.

The psoriasis therapeutics market encompasses a range of medical treatments designed to alleviate the symptoms of psoriasis, a chronic autoimmune skin disease characterized by red, scaly patches. With a focus on managing inflammation and skin cell proliferation, treatment options include topical agents, phototherapy, and systemic medications like biologics targeting specific immune pathways. The necessity of advancing psoriasis therapeutics stems from the disease's impact on patients' quality of life and the limited efficacy and safety of traditional treatments. These therapeutics are applied across diverse settings, including hospitals, specialty clinics, and home care, addressing both health-related quality improvement and economic burden concerns. The market's expansion is propelled by an increasing prevalence of psoriasis, growing awareness, and advancements in biotechnology. Key influencing factors include rising patient demand for efficient treatments, new drug approvals, and technological advancements in biologics and small molecules. One notable opportunity lies in personalized medicine, particularly the development of tailor-made biologics, fostering more effective patient outcomes. Market players are also exploring new therapy areas, such as small-molecule inhibitors and gene therapies, which underline significant growth potential.

KEY MARKET STATISTICS
Base Year [2023] USD 21.62 billion
Estimated Year [2024] USD 23.71 billion
Forecast Year [2030] USD 41.55 billion
CAGR (%) 9.77%

Conversely, growth is hampered by challenges such as high treatment costs, stringent regulatory processes, and side-effects associated with long-term use of certain therapies. Patient adherence may further complicate the market landscape due to the chronic nature of psoriasis. Innovation lies in researching novel biologic agents with enhanced efficacy and safety profiles, exploring telemedicine for remote patient management, and leveraging AI for improved patient stratification and treatment regimens. The market shows a dynamic and receptive nature, yet continuous investment in research and overcoming these challenges will be vital for sustained growth. Businesses are recommended to prioritize strategic partnerships, expand pipeline products, and engage in comprehensive digital marketing campaigns to capture emerging market opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Psoriasis Therapeutics Market

The Psoriasis Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing elderly population worldwide
    • Increasing incidence of plaque psoriasis and psoriasis arthritis
    • Favorable reimbursement policies for such therapeutics
  • Market Restraints
    • High cost of therapeutics
  • Market Opportunities
    • Rising prescription volume and approvals of biologic products
    • Emerging development of new biologics and novel pipeline drugs
  • Market Challenges
    • Probable health risks due to the medication

Porter's Five Forces: A Strategic Tool for Navigating the Psoriasis Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Psoriasis Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Psoriasis Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Psoriasis Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Psoriasis Therapeutics Market

A detailed market share analysis in the Psoriasis Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Psoriasis Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Psoriasis Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Psoriasis Therapeutics Market

A strategic analysis of the Psoriasis Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Psoriasis Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen, Inc., Astellas Pharma Inc., AstraZeneca Plc, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson services, inc, LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Pfizer Inc, and Sun Pharmaceutical Industries Limited.

Market Segmentation & Coverage

This research report categorizes the Psoriasis Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Molecule, market is studied across Biologics and Small Molecules.
  • Based on Route of Administration, market is studied across Oral, Parenteral, and Topical.
  • Based on Dosage Forms, market is studied across Liquid, Semi-Solid, and Solid.
  • Based on Mechanism of Action, market is studied across IL Blocker, PDE4 Inhibitors, and TNF Inhibitors.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing elderly population worldwide
      • 5.1.1.2. Increasing incidence of plaque psoriasis and psoriasis arthritis
      • 5.1.1.3. Favorable reimbursement policies for such therapeutics
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising prescription volume and approvals of biologic products
      • 5.1.3.2. Emerging development of new biologics and novel pipeline drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Probable health risks due to the medication
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Psoriasis Therapeutics Market, by Molecule

  • 6.1. Introduction
  • 6.2. Biologics
  • 6.3. Small Molecules

7. Psoriasis Therapeutics Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral
  • 7.4. Topical

8. Psoriasis Therapeutics Market, by Dosage Forms

  • 8.1. Introduction
  • 8.2. Liquid
  • 8.3. Semi-Solid
  • 8.4. Solid

9. Psoriasis Therapeutics Market, by Mechanism of Action

  • 9.1. Introduction
  • 9.2. IL Blocker
  • 9.3. PDE4 Inhibitors
  • 9.4. TNF Inhibitors

10. Americas Psoriasis Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Psoriasis Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Psoriasis Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen, Inc.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca Plc
  • 5. Bausch Health Companies Inc.
  • 6. Boehringer Ingelheim International GmbH
  • 7. Eli Lilly and Company
  • 8. F. Hoffmann-La Roche AG
  • 9. GlaxoSmithKline plc
  • 10. Johnson & Johnson services, inc
  • 11. LEO Pharma A/S
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Pfizer Inc
  • 15. Sun Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. PSORIASIS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PSORIASIS THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PSORIASIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PSORIASIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PSORIASIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PSORIASIS THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEMI-SOLID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SOLID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL BLOCKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 190. PSORIASIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. PSORIASIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023